Cagrilintide molecular structure
Cagrilintide molecular structure
Clinical Trial
🏋️Weight Loss

Cagrilintide

Also known as: NN9838, AM833, Long-Acting Amylin Analog

MW

3946.50 Da

CAS

2375268-81-0

Routes

1 route

Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk for obesity treatment. Amylin is a 37-amino acid peptide co-secreted with insulin from pancreatic beta cells that promotes satiety, delays gastric emptying, and suppresses glucagon. Cagrilintide features amino acid modifications and a C18 fatty acid chain enabling once-weekly dosing through albumin binding. Most notably, cagrilintide is being developed in combination with semaglutide (CagriSema), which targets two complementary satiety pathways — amylin (hindbrain area postrema/NTS) and GLP-1 (hypothalamic and brainstem). The Phase 2 REDEFINE trial of CagriSema showed 15.6% weight loss at 32 weeks, with Phase 3 trials (REDEFINE program) underway.

Research Use Only— For educational and research purposes only

Research Applications

Obesity (CagriSema Combination)

Phase 3 REDEFINE program testing cagrilintide + semaglutide 2.4 mg. Phase 2 showed 15.6% weight loss at 32 weeks.

Obesity (Monotherapy)

Phase 2 data showed ~10% weight loss with cagrilintide alone, establishing independent efficacy.

Type 2 Diabetes

Being studied for glycemic control in combination with semaglutide.

Mechanism of Action

Amylin Receptor Complex Activation

Cagrilintide activates the amylin receptor — a heterodimer of the calcitonin receptor (CTR) with receptor activity-modifying proteins (RAMPs, primarily RAMP1-3). This receptor complex is distinct from GLP-1R, providing complementary satiety signaling primarily through the area postrema and nucleus tractus solitarius in the brainstem.

Satiety Through Distinct Pathways

While GLP-1 acts primarily on hypothalamic appetite centers, amylin acts on brainstem satiety circuits — a fundamentally different neural pathway. This explains the additive weight loss observed with CagriSema (cagrilintide + semaglutide) combination.

Biological Pathways

CTR/RAMP/cAMP signaling in area postrema neurons. Brainstem NTS integration of satiety signals. Vagal afferent activation for gastric emptying delay. ERK1/2 signaling for neuronal activation in satiety centers.

Dosage Information

Typical dosage ranges for research applications. Always verify with current literature.
Typical Dose
2,400 mcg
Dose Range
250 - 4,500 mcg
Frequency
Once weekly; titrate from 250 mcg over 16 weeks
Dosage Calculator
Calculate precise peptide dosages based on your reconstitution parameters
Dosage calculation parameters
Vial size in milligrams
Reconstitution volume in milliliters
Body weight input
Recommended dose per kg
mcg/kg
Desired dose input
mcg

Calculation Results

Concentration
2.5 mg/ml
Dose Volume
0.1 ml0.100 ml
Insulin Syringe
10 units
Doses per Vial
2020 doses @ 250 mcg

Syringe Fill Level (100u syringe)

05010010.0uunits
0u10.0 / 100 units (10%)100u

Protocols

No protocols featuring this peptide yet.

Browse All Protocols

Stability & Storage

Investigational compound. Once-weekly subcutaneous injection. The C18 fatty acid acylation provides albumin binding for extended half-life. Store investigational supply at 2-8°C.

Side Effects & Precautions

GI effects (nausea 20-30%, vomiting, diarrhea) similar to other incretin-based therapies. Injection site reactions. The combination with semaglutide shows GI effects comparable to semaglutide alone, suggesting amylin agonism does not substantially add to GI burden.

Research Use Only. This information is for educational and research purposes only. Not intended for medical advice or self-medication.

Regulatory Status

Clinical Trial

Investigational — Phase 3 clinical trials ongoing (REDEFINE program for CagriSema). Not yet approved by any regulatory authority. Novo Nordisk plans regulatory submissions based on Phase 3 data.

Research Studies

Cagrilintide Plus Semaglutide for Obesity (REDEFINE 1 Phase 2)

Enebo LB, Berthelsen KK, Kankam M, et al.

Lancet
2021
View Source

Amylin Analogs for Obesity Treatment

Hay DL, Chen S, Lutz TA, et al.

Trends in Pharmacological Sciences
2015
View Source
Dosage Calculator
Calculate reconstitution volumes and injection amounts for Cagrilintide.
Open Calculator
Explore More
Explore more peptides in the Weight Loss category and related research.
View Weight Loss Category